Best ETF Areas of Last Week
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 11 2024
0mins
Source: NASDAQ.COM
Wall Street Performance:
- S&P 500, Dow Jones, and Nasdaq Composite all saw gains last week due to easing inflation, soft manufacturing data, and a tech rally.
- Treasury yields declined, boosting the market rally, with technology stocks seeing significant inflows.
US Economy:
- The US economy added 272,000 jobs in May 2024, the highest in five months, surpassing forecasts and previous monthly gains.
Winning ETF Areas:
- Bitcoin Miners ETFs surged, reflecting confidence in potential Fed rate cuts.
- Natural Gas ETFs rose as natural gas maintains a critical role in U.S. electricity generation.
- Semiconductor ETFs performed well, driven by NVIDIA's growth in AI chips for data centers.
Weight-Loss Drugs:
- Weight loss drug manufacturers' shares increased, with expectations of a growing market due to rising obesity rates.
- Intense competition exists among companies producing GLP-1 medicines, seen as revolutionary in the pharmaceutical industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVO
Wall Street analysts forecast NVO stock price to rise
8 Analyst Rating
4 Buy
3 Hold
1 Sell
Moderate Buy
Current: 44.390
Low
42.00
Averages
54.67
High
70.00
Current: 44.390
Low
42.00
Averages
54.67
High
70.00
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Viking Therapeutics Faces Competitive Pressures
- Intensifying Market Competition: Viking Therapeutics' weight-loss candidate VK2735 showed promising results in clinical trials, but increasing competition from new product launches by Eli Lilly and Novo Nordisk may impact Viking's market share significantly.
- Dramatic Stock Price Decline: Viking's stock price has plummeted from nearly $100 to below $30, reflecting investor pessimism regarding its future prospects, particularly in light of stronger competitors entering the market.
- Cash Burn Risks: With approximately $603 million in cash on hand but burning through about $114 million per quarter, Viking may face dilution risks if it fails to raise additional funds soon, further undermining investor confidence.
- Slow Clinical Progress: Although VK2735 remains in clinical trials, competitors are advancing in drug development, potentially placing Viking at a disadvantage in the market and affecting its long-term growth potential.
See More
Eli Lilly's Strong Performance in the Intensifying GLP-1 Drug Competition
- Market Share Competition: Eli Lilly's Mounjaro and Zepbound achieved impressive sales growth of 125% and 80% respectively in Q1 2026, demonstrating strong performance in the GLP-1 market, even as Novo Nordisk introduced its oral GLP-1 drug, with Eli Lilly maintaining its lead.
- Indian Market Dynamics: Despite Novo Nordisk's Wegovy losing patent protection in India, leading to an influx of low-cost generics, Eli Lilly's Mounjaro still saw a 10% sales increase in that market, indicating its product remains attractive amidst competition.
- International Market Advantage: Morgan Stanley estimates that Eli Lilly controls over 50% of the international market, driven by Mounjaro's superior weight-loss results, suggesting continued growth potential as consumers seek effective weight-loss solutions.
- Valuation Considerations: While Eli Lilly's price-to-earnings ratio stands at approximately 38x, down from a five-year average of 56x, it may not attract value investors; however, aggressive growth investors might reconsider its long-term international opportunities, particularly in the Indian market.
See More
Viking Therapeutics Stock Plummets, Future Uncertain
- Significant Stock Decline: Viking Therapeutics' stock has plummeted from nearly $100 to below $30, indicating a sharp decline in investor confidence, particularly as competitors like Novo Nordisk and Eli Lilly continue to launch new drugs.
- Disappointing Clinical Trial Results: Although VK2735 showed promising results in early trials, subsequent data revealed worse-than-expected side effects, leading to a negative shift in public perception and investor sentiment.
- Increasing Cash Burn: With approximately $603 million in cash on hand but burning through about $114 million per quarter, Viking may face the risk of share dilution if it fails to raise additional funds soon, further undermining shareholder confidence.
- Intensifying Market Competition: As Viking strives to bring its weight-loss drug to market, larger competitors like Novo Nordisk and Eli Lilly are developing more potent new treatments, making the future market landscape increasingly challenging for Viking and casting doubt on its prospects.
See More
Eli Lilly Reports Strong Results for GLP-1 Drugs Amidst Competition
- Significant Sales Growth: In Q1 2026, Eli Lilly's Mounjaro and Zepbound saw sales increase by 125% and 80% respectively, demonstrating robust performance in the GLP-1 market and reinforcing its leadership position.
- International Market Advantage: Despite the influx of low-cost generics in India, Mounjaro's sales grew by 10%, indicating sustained consumer appeal and potentially laying the groundwork for future international expansion.
- Market Share Increase: Morgan Stanley estimates that Eli Lilly controls over 50% of the international market, driven by Mounjaro's superior weight-loss results, suggesting strong growth potential globally.
- Valuation Considerations: While Eli Lilly's price-to-earnings ratio stands at approximately 38x, down from a five-year average of 56x, it may not attract value investors; however, aggressive growth investors might reassess its long-term opportunities in the international market.
See More
Eli Lilly's Dominance in Weight Loss Drug Market
- Market Share Leadership: Eli Lilly has captured 60% of the U.S. weight loss drug market, surpassing Novo Nordisk, which highlights its strong competitive position in the rapidly growing healthcare sector, with the market expected to reach $100 billion in value by the next decade.
- Breakthrough in Drug Development: Lilly's new candidate, retatrutide, demonstrated impressive results in a phase 3 trial, with the highest dose helping patients lose an average of 28% of their body weight over 80 weeks, and 45% of participants losing more than 30%, indicating its potential to outperform existing products.
- Multiple Mechanism of Action: Retatrutide acts on three hormonal pathways related to appetite and blood sugar management, while Novo Nordisk's drugs target only one pathway, suggesting that retatrutide may offer greater weight loss potential and could become a new favorite in the market.
- Future Market Outlook: With retatrutide's strong efficacy and safety profile, Lilly is poised to apply for regulatory approval in the coming years, further solidifying its market position and potentially delivering high returns for investors as the value of the weight loss drug market continues to rise.
See More
Eli Lilly's Breakthrough Weight Loss Drug Trial Success
- Market Share Leadership: Eli Lilly has captured a 60% share of the U.S. GLP-1 market, surpassing early leader Novo Nordisk by launching the dual agonist tirzepatide (Mounjaro and Zepbound), demonstrating its competitive edge in the rapidly growing weight loss drug sector.
- Clinical Trial Success: Lilly's new candidate retatrutide showed remarkable results in a phase 3 trial, with patients losing an average of 28% of their body weight over 80 weeks, and over 30% of participants losing more than 30%, indicating its potential as a more effective weight loss solution compared to existing products.
- Safety and Compliance: The lowest dose of retatrutide had a discontinuation rate of 4.1%, lower than the placebo rate of 4.9%, suggesting that its side effects align with those of current GLP-1 drugs, which may enhance patient adherence and strengthen market competitiveness.
- Future Market Potential: With the weight loss drug market projected to reach $100 billion in the next decade, this breakthrough medication positions Eli Lilly to potentially deliver another blockbuster product, further solidifying its leadership in the field and generating high returns for investors.
See More
Viking Therapeutics Faces Competitive Pressures
- Intensifying Market Competition: Viking Therapeutics' weight-loss candidate VK2735 showed promising results in clinical trials, but increasing competition from new product launches by Eli Lilly and Novo Nordisk may impact Viking's market share significantly.
- Dramatic Stock Price Decline: Viking's stock price has plummeted from nearly $100 to below $30, reflecting investor pessimism regarding its future prospects, particularly in light of stronger competitors entering the market.
- Cash Burn Risks: With approximately $603 million in cash on hand but burning through about $114 million per quarter, Viking may face dilution risks if it fails to raise additional funds soon, further undermining investor confidence.
- Slow Clinical Progress: Although VK2735 remains in clinical trials, competitors are advancing in drug development, potentially placing Viking at a disadvantage in the market and affecting its long-term growth potential.
See More
Eli Lilly's Strong Performance in the Intensifying GLP-1 Drug Competition
- Market Share Competition: Eli Lilly's Mounjaro and Zepbound achieved impressive sales growth of 125% and 80% respectively in Q1 2026, demonstrating strong performance in the GLP-1 market, even as Novo Nordisk introduced its oral GLP-1 drug, with Eli Lilly maintaining its lead.
- Indian Market Dynamics: Despite Novo Nordisk's Wegovy losing patent protection in India, leading to an influx of low-cost generics, Eli Lilly's Mounjaro still saw a 10% sales increase in that market, indicating its product remains attractive amidst competition.
- International Market Advantage: Morgan Stanley estimates that Eli Lilly controls over 50% of the international market, driven by Mounjaro's superior weight-loss results, suggesting continued growth potential as consumers seek effective weight-loss solutions.
- Valuation Considerations: While Eli Lilly's price-to-earnings ratio stands at approximately 38x, down from a five-year average of 56x, it may not attract value investors; however, aggressive growth investors might reconsider its long-term international opportunities, particularly in the Indian market.
See More
Viking Therapeutics Stock Plummets, Future Uncertain
- Significant Stock Decline: Viking Therapeutics' stock has plummeted from nearly $100 to below $30, indicating a sharp decline in investor confidence, particularly as competitors like Novo Nordisk and Eli Lilly continue to launch new drugs.
- Disappointing Clinical Trial Results: Although VK2735 showed promising results in early trials, subsequent data revealed worse-than-expected side effects, leading to a negative shift in public perception and investor sentiment.
- Increasing Cash Burn: With approximately $603 million in cash on hand but burning through about $114 million per quarter, Viking may face the risk of share dilution if it fails to raise additional funds soon, further undermining shareholder confidence.
- Intensifying Market Competition: As Viking strives to bring its weight-loss drug to market, larger competitors like Novo Nordisk and Eli Lilly are developing more potent new treatments, making the future market landscape increasingly challenging for Viking and casting doubt on its prospects.
See More
Eli Lilly Reports Strong Results for GLP-1 Drugs Amidst Competition
- Significant Sales Growth: In Q1 2026, Eli Lilly's Mounjaro and Zepbound saw sales increase by 125% and 80% respectively, demonstrating robust performance in the GLP-1 market and reinforcing its leadership position.
- International Market Advantage: Despite the influx of low-cost generics in India, Mounjaro's sales grew by 10%, indicating sustained consumer appeal and potentially laying the groundwork for future international expansion.
- Market Share Increase: Morgan Stanley estimates that Eli Lilly controls over 50% of the international market, driven by Mounjaro's superior weight-loss results, suggesting strong growth potential globally.
- Valuation Considerations: While Eli Lilly's price-to-earnings ratio stands at approximately 38x, down from a five-year average of 56x, it may not attract value investors; however, aggressive growth investors might reassess its long-term opportunities in the international market.
See More
Eli Lilly's Dominance in Weight Loss Drug Market
- Market Share Leadership: Eli Lilly has captured 60% of the U.S. weight loss drug market, surpassing Novo Nordisk, which highlights its strong competitive position in the rapidly growing healthcare sector, with the market expected to reach $100 billion in value by the next decade.
- Breakthrough in Drug Development: Lilly's new candidate, retatrutide, demonstrated impressive results in a phase 3 trial, with the highest dose helping patients lose an average of 28% of their body weight over 80 weeks, and 45% of participants losing more than 30%, indicating its potential to outperform existing products.
- Multiple Mechanism of Action: Retatrutide acts on three hormonal pathways related to appetite and blood sugar management, while Novo Nordisk's drugs target only one pathway, suggesting that retatrutide may offer greater weight loss potential and could become a new favorite in the market.
- Future Market Outlook: With retatrutide's strong efficacy and safety profile, Lilly is poised to apply for regulatory approval in the coming years, further solidifying its market position and potentially delivering high returns for investors as the value of the weight loss drug market continues to rise.
See More
Eli Lilly's Breakthrough Weight Loss Drug Trial Success
- Market Share Leadership: Eli Lilly has captured a 60% share of the U.S. GLP-1 market, surpassing early leader Novo Nordisk by launching the dual agonist tirzepatide (Mounjaro and Zepbound), demonstrating its competitive edge in the rapidly growing weight loss drug sector.
- Clinical Trial Success: Lilly's new candidate retatrutide showed remarkable results in a phase 3 trial, with patients losing an average of 28% of their body weight over 80 weeks, and over 30% of participants losing more than 30%, indicating its potential as a more effective weight loss solution compared to existing products.
- Safety and Compliance: The lowest dose of retatrutide had a discontinuation rate of 4.1%, lower than the placebo rate of 4.9%, suggesting that its side effects align with those of current GLP-1 drugs, which may enhance patient adherence and strengthen market competitiveness.
- Future Market Potential: With the weight loss drug market projected to reach $100 billion in the next decade, this breakthrough medication positions Eli Lilly to potentially deliver another blockbuster product, further solidifying its leadership in the field and generating high returns for investors.
See More
